Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1a/1b First-in-Human Trial of LY4175408 in Advanced Solid Tumors
jRCT2051250100Phase 1Recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 1, open-label trial of LY4175408 in non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), endometrial cancer (EC) and 2 more (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants with Dose Limiting Toxicities of LY4175408 (Phase 1a) and Overall Response Rate (ORR) (Phase 1b). Started Nov 2025; status: recruiting.
02
Drugs
LY4175408
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)endometrial cancer (EC)triple-negative breast cancer (TNBC)solid tumor
Beyond the preview
Go deeper on jRCT2051250100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051250100.